Navigation Links
Questcor Reports Record Second Quarter Financial Results
Date:7/24/2014

nded June 30, 2014, compared with $12.2 million for the year ago period. The increased R&D expense reflects the Company's ongoing efforts to further build the body of clinical evidence for Acthar, clarify the potential immune-modulating properties of Acthar and Synacthen Depot, and identify mechanisms of action that potentially could be applicable to other inflammatory and auto-immune diseases with high unmet medical needs. R&D expense in the second quarter of 2014 includes an upfront payment of $3.3 million to a third party in connection with a research and development agreement. 

The Company is also identifying new patient populations in which to evaluate both Acthar and Synacthen Depot through exploratory clinical studies. Questcor is presently funding research and development for Acthar in the following indications:

New Indications for Label Enhancement Programs:

  • Amyotrophic Lateral Sclerosis (ALS): Patient enrollment has been completed in a company-sponsored dose-ranging Phase 2 clinical trial to evaluate the safety and tolerability of Acthar in patients with ALS, often referred to as Lou Gehrig's disease. ALS is a life-threatening, progressive neurodegenerative disease that affects nerve cells in the brain and the spinal cord.
  • Diabetic Nephropathy: Enrollment continues in a company-sponsored Phase 2 trial to evaluate the efficacy and safety of Acthar in patients with diabetic nephropathy, one of the most common causes of end-stage renal disease in the United States.
  • Acute Respiratory Distress Syndrome (ARDS): Site selection has been initiated for a Phase 2 study to explore the safety and efficacy of Acthar in patients with ARDS. ARDS is an acute life threatening lung condition that can result from pulmonary and non-pulmonary infections or a multitude of other serious conditions.
  • Clinical Trials Supporting Approved Indications:

  • Idiopathic Membranous Nephropathy: Enrollment continues in
    '/>"/>

  • SOURCE Questcor Pharmaceuticals, Inc.
    Copyright©2014 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28

    Related medicine technology :

    1. Mallinckrodt Pharmaceuticals And Questcor Pharmaceuticals Provide Update On Transaction
    2. Questcor Pharmaceuticals to Present at the J.P. Morgan Healthcare Conference
    3. Products Recall, Stock Price Updates, Technology Solution Deployment, Update on Extension Trial, and Donations - Research Report on Alexion Pharma, Questcor, BioMarin Pharma, Allscripts, and Prana
    4. Questcor Provides Donation In Support Of Childrens Hospital & Research Center Oakland
    5. Partnerships, Appointments, New Products, Public Offerings, and Agreements - Research Report on Questcor Pharmaceuticals, Hologic, IDEXX, Endologix, and Healthways
    6. Questcor Announces Quarterly Cash Dividend and Provides Update on Share Repurchase Program
    7. Questcor Pharmaceuticals to Present at the Oppenheimer Annual Healthcare Conference
    8. Biologics License Applications, Event Participations, and Stock Movements - Research Report on Baxter, WellPoint, Questcor Pharmaceuticals, CareFusion, and Hologic
    9. Product Reviews, Recognitions, FDA Responses, and New Leadership Appointments - Research Report on Gilead, WellPoint, Questcor, Forest Laboratories, and Envision Healthcare
    10. Questcor Honored as an "Everyday Hero" by NephCure Foundation
    11. Questcor Adds G. Kelly Martin to Board of Directors
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:4/21/2015)... SAN FRANCISCO , April 21, 2015   ... focusing on the advancement of cardiac care, announced today ... care systems in the U.S., will now be offering ... of long-term continuous cardiac monitoring. "At Banner ... by improving patient outcomes and services," said John ...
    (Date:4/21/2015)... , April 21, 2015  Decision Diagnostics Corp. ... and the exclusive worldwide sales, service and regulatory ... FDA-cleared Green Alternative Strip, specifically designed to work ... OneTouch Ultra family of glucose testing meters, the ... today that Johnson & Johnson/Lifescan has requested an ...
    (Date:4/21/2015)... , April 21, 2015  CryoLife, Inc. (NYSE: ... company focused on cardiac and vascular surgery, announced today ... on Tuesday, April 28, 2015.  On that day, the ... at 10:00 a.m. Eastern Time to discuss the results, ... Pat Mackin , Chairman, President and Chief Executive ...
    Breaking Medicine Technology:Banner Health to Offer iRhythm ZIO Service for Continuous Cardiac Monitoring 2Banner Health to Offer iRhythm ZIO Service for Continuous Cardiac Monitoring 3Decision Diagnostics Shrugs Off New Attack As Johnson & Johnson Panics In Patent Case 2Decision Diagnostics Shrugs Off New Attack As Johnson & Johnson Panics In Patent Case 3CryoLife Announces Release Date and Teleconference Call Details for 2015 First Quarter Financial Results 2
    ... -- Chindex International, Inc. (NASDAQ: ... care services in China through the operations of United ... and affiliated ambulatory clinics, today announced that the Company ... and first half of 2011, which ended June 30, ...
    ... Apnex Medical, Inc., received investigational device exemption (IDE) approval ... begin a clinical study to evaluate the safety and ... treat obstructive sleep apnea (OSA). Data from this clinical ... application for the HGNS System to the FDA. ...
    Cached Medicine Technology:Chindex International, Inc. to Report Financial Results for the Second Quarter and First Half of 2011 2Apnex Medical, Inc. Receives FDA Approval for Pivotal Clinical Study for Obstructive Sleep Apnea 2Apnex Medical, Inc. Receives FDA Approval for Pivotal Clinical Study for Obstructive Sleep Apnea 3
    (Date:4/21/2015)... PA (PRWEB) April 21, 2015 Grafika ... County commercial printer, Offset Impressions. , “We’re ... full line of printing capabilities and knowledgeable team members,” ... “This acquisition allows us to offer an ever wider ... the labeling, packaging, and specialty services we already offer. ...
    (Date:4/21/2015)... SAN DIEGO (PRWEB) April 21, 2015 ... representing more than 275 leading life sciences organizations, ... CEO Sara Radcliffe regarding California State Assembly Bill ... sciences sector dedicated to the development of treatments ... diseases, we have deep concerns regarding AB 463, ...
    (Date:4/21/2015)... Information is the best weapon in the ... empowers patients and their families with knowledge about living with ... Cancer is the Answer" and new website . , ... guide patients from diagnosis through treatment and even death. The ... their treatment, at home and in the examination room. , ...
    (Date:4/21/2015)... Dallas, Texas (PRWEB) April 21, 2015 ... Review, H1 2015” provides comparative analysis on ... report strengthens R&D pipelines by identifying new ... best-in-class products. Complete report with TOC is ... The report also reviews key players involved ...
    (Date:4/21/2015)... Dallas, Texas (PRWEB) April 21, 2015 ... Global Sodium Citrate Industry is a professional and ... global Sodium Citrate Market with a ... companies included in the sodium citrate market research ... Acid Chemicals, Natural Biological, Cofco Biochemical, Capchem, Lianyungang ...
    Breaking Medicine News(10 mins):Health News:California Healthcare Institute Statement on AB 463 2Health News:California Healthcare Institute Statement on AB 463 3Health News:Authoritative guide and new accompanying therapeutic web portal bridge information gaps in cancer treatment 2Health News:Dermatitis Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com 2Health News:Dermatitis Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com 3Health News:Dermatitis Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com 4Health News:Sodium Citrate Industry Global Key Manufacturers Analysis Report 2015-2020 2Health News:Sodium Citrate Industry Global Key Manufacturers Analysis Report 2015-2020 3
    ... South Plantation High School One of the 25 Healthiest Schools in the ... ... Dec. 11 The ,got milk?(R), Milk,Mustache marketing campaign, in association with ... today that South Plantation High School has been selected as one,of the ...
    ... LAKE CITY, Dec. 11 Amedica Corporation, an,orthopedic ... today that the U.S. Food and Drug Administration,has ... Valeo(TM),ceramic VBR spinal implant., The Valeo VBR ... aid in surgical correction and stabilization of the ...
    ... meat you eat, the higher the risk , , TUESDAY, Dec. ... pork chop eaten daily could put you at increased risk ... , The more red meat and processed meat you ... Cancer Institute concluded. , "Red and processed meats have ...
    ... Inc., a,developer of innovative technologies and products ... provider of QuantiGene(R) and,QuantiGene Plex(R) products for ... they have been awarded Frost & Sullivan,s ... of the Year,Award. Frost & Sullivan, a ...
    ... is a time for,office parties, sweet snacks, and big ... and December can be a tough time to,stay fit. ... health,clubs, says adding a few extra steps to everyday ... to this report from 24 Hour Fitness at:, http://media.medialink.com/WebNR.aspx?story=34206 ...
    ... Cardica, Inc.,(Nasdaq: CRDC ) today announced the ... underwriters of Cardica,s November 2007 underwritten,public offering. The ... common stock from Cardica at a purchase price ... L.L.C. acted as the sole book-running manager,of the ...
    Cached Medicine News:Health News:Local School Wins National got milk?(R) Healthiest Student Bodies Contest 2Health News:Local School Wins National got milk?(R) Healthiest Student Bodies Contest 3Health News:Amedica Receives FDA Special 510(k) Clearance for its Valeo(TM) Ceramic Spinal Implant 2Health News:High Meat Consumption Linked to Heightened Cancer Risk 2Health News:High Meat Consumption Linked to Heightened Cancer Risk 3Health News:High Meat Consumption Linked to Heightened Cancer Risk 4Health News:Panomics Inc.: Recipient of the Frost & Sullivan 2007 United States Drug Discovery Technologies Entrepreneurial Company of the Year Award 2Health News:Panomics Inc.: Recipient of the Frost & Sullivan 2007 United States Drug Discovery Technologies Entrepreneurial Company of the Year Award 3Health News:Cardica Announces Exercise of Over-Allotment Option 2Health News:Cardica Announces Exercise of Over-Allotment Option 3
    The Model 340DT is a new desk top pulse oximeter that was designed for continuous pulse oximetry and has visual and audible alarms to aid with patient monitoring....
    ... has expanded memory capabilities for overnight sleep screening., ... oxygen saturation and pulse rate data, and can ... your needs:, ,1. The Model 130 can ... a single patient, making the device ideally suited ...
    ... Cost-effective, portable, continuous, or ... system with alarms and an ... Home-Use and Sleep Study modes ... in the hospital or clinical ...
    ... The Autocorr Plus, the fourth in ... versatile pulse oximeter/ECG/Respiration Monitor, with 3 ... digital oximetry with SAC (Serial Autocorrelation) ... electroluminescent screen display provides two user ...
    Medicine Products: